Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235219 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03235219 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 39 participants.
The verdict
NCT03235219, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this Phase 1b study is to assess the safety and tolerability of JNJ-64565111 in adult men and women (of non-child bearing potential) with Type 2 Diabetes Mellitus.
Interventions
- DRUG Placebo
- DRUG JNJ-64565111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2018-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03235219
The ClinicalTrials.gov registry entry for NCT03235219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03235219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03235219 about?
NCT03235219 is a clinical study titled "A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus". The purpose of this Phase 1b study is to assess the safety and tolerability of JNJ-64565111 in adult men and women (of non-child bearing potential) with Type 2 Diabetes Mellitus.
What is the current status of trial NCT03235219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2017-08-01. Estimated completion is 2018-02-19.
What interventions are being tested in trial NCT03235219?
The interventions under investigation include: Placebo (DRUG), JNJ-64565111 (DRUG).
Who is sponsoring clinical trial NCT03235219?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.